Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Accenture
Argus Health
Farmers Insurance
McKinsey
Fuji
Harvard Business School
Chubb

Generated: May 27, 2018

DrugPatentWatch Database Preview

SULAR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Sular patents expire, and what generic alternatives are available?

Sular is a drug marketed by Covis Pharma Bv and is included in one NDA.

The generic ingredient in SULAR is nisoldipine. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nisoldipine profile page.
Drug patent expirations by year for SULAR
Pharmacology for SULAR
Medical Subject Heading (MeSH) Categories for SULAR
Synonyms for SULAR
(.+/-.)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate
(.+/-.)-Nisoldipine
(+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate
(+/-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic Acid Isobutyl Methyl Ester
1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester
2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-methyl ester O5-(2-methylpropyl) ester
3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #
3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (.+/-.)-
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (+-)-
63675-72-9
675N729
A834466
AB0106136
AB01275444_02
AB01275444-01
AB2000270
AC-987
AC1L1IAY
AK143131
AKOS005563632
AN-6975
Bay k 5552
BAY k-5552
BAY-k 5552
Bay-k-5552
Baymycard
BBL028683
BC204167
BDBM50101963
BIDD:GT0684
Bio-0177
BRD-A84465106-001-01-2
BRN 0454188
C07699
C20H24N2O6
CAS-63675-72-9
CCG-100894
CCG-213412
CHEBI:76917
CHEMBL1726
CHEMBL3192341
CHEMBL441428
CPD004727075
CS-1131
CTK8G1888
D00618
D0S5CU
DB00401
DL-255
DR002237
DSSTox_CID_3371
DSSTox_GSID_23371
DSSTox_RID_76999
DTXSID0023371
EINECS 264-407-7
FT-0082489
FT-0601599
GTPL2524
HE370488
HMS2051O18
HMS2089K20
HMS2093F15
HMS2097E13
HMS2231L20
HMS3393O18
HMS3651K17
HY-17402
Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat
Isobutyl Methyl 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate
isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
J10291
KM0774
KS-000001QK
KS-5188
LS-131295
MCULE-5009799152
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
MFCD00478055
MLS000759498
MLS001424102
MLS002153943
MolPort-003-666-664
N0900
NC00144
NCGC00164633-01
NCGC00164633-02
NCGC00164633-03
NCGC00255136-01
Nisocor
Nisoldipin
Nisoldipina
nisoldipine
Nisoldipine (JAN/USAN/INN)
nisoldipine (product)
Nisoldipine [USAN:BAN:INN:JAN]
Nisoldipine [USAN:INN:BAN:JAN]
Nisoldipine, >=98% (HPLC)
Nisoldipine, ~97%
Nisoldipine;
Nisoldipino
Nisoldipino [INN-Spanish]
Nisoldipinum
Nisoldipinum [INN-Latin]
NSC-759106
NSC759106
O3-methyl O5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
O5-isobutyl O3-methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
O5-methyl O3-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Pharmakon1600-01505390
s1748
SAM001246719
SBI-0206830.P001
SC-18015
SCHEMBL39779
SMR000466370
SR-05000002009
SR-05000002009-3
ST24042247
STK631543
Sular (TN)
Syscor
Tox21_112251
Tox21_112251_1
Tox21_302365
VKQFCGNPDRICFG-UHFFFAOYSA-N
Z277942268
Zadipina
Zadipina;Bay k 5552;Baymycard;Sular

US Patents and Regulatory Information for SULAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-008 Jan 2, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-005 Jan 2, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-002 Feb 2, 1995 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for SULAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-002 Feb 2, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-001 Feb 2, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-008 Jan 2, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SULAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 8.5 mg and 17 mg ➤ Subscribe 2009-03-02
➤ Subscribe Extended-release Tablets 25.5 mg and 34 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 20 mg and 30 mg ➤ Subscribe 2007-11-07
➤ Subscribe Extended-release Tablets 40 mg ➤ Subscribe 2007-06-11

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
Merck
Queensland Health
Fuji
Johnson and Johnson
Cipla
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.